8-K/AEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K/A Report, Financial Results (Sep 1, 2005)

Filed September 1, 2005For Securities:BMYCELG-RIBMYMP

Summary

This Form 8-K/A filing from Bristol-Myers Squibb Company (BMY) serves as an amendment to a previous 8-K filing dated July 28, 2005. The primary purpose of this amendment is to provide revised supplemental financial information as of June 30, 2005, and March 31, 2005. This updated information includes details on net sales, months on hand inventory, and demand for key products across the International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare reporting segments. Investors should note that this amendment focuses on clarifying and enhancing the previously reported quarterly results by providing more granular data for key product performance and inventory levels. While the amendment does not introduce new financial results or material events, it offers greater transparency into the operational drivers behind BMY's performance in its major segments, allowing for a more informed assessment of inventory management and product demand trends.

Key Highlights

  • 1Amendment to a previous Form 8-K filed on July 28, 2005.
  • 2Provides revised supplemental financial information for the periods ending June 30, 2005, and March 31, 2005.
  • 3The revised information includes net sales, months on hand (inventory), and demand data for key products.
  • 4Details are segmented for International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare reporting segments.
  • 5This filing enhances transparency by offering more granular data on product performance and inventory levels.
  • 6The amendment incorporates by reference revised supplemental information posted on the company's website (www.bms.com).

Frequently Asked Questions

The main purpose of this 8-K/A filing is to amend a previous 8-K filing from July 28, 2005, by providing revised supplemental financial information. This includes updated net sales, inventory levels (months on hand), and demand data for key products as of June 30, 2005, and March 31, 2005.

The revised data pertains to net sales, months on hand inventory, and demand information for key products within the International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare reporting segments. This information is for the periods ending June 30, 2005, and March 31, 2005.

No, this filing does not introduce new material events or entirely new financial results. It serves to clarify and enhance the previously reported second-quarter 2005 results by providing more detailed operational and inventory data.

The revised supplemental information is incorporated by reference as Exhibit 99.2 to this Form 8-K/A and was posted on Bristol-Myers Squibb Company's website at www.bms.com.